



## Financial Tear Sheet

### Corporate Profile

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders.

### Primary IR Contact

MacDougall Biomedical  
Communications  
Karen Sharma

**Phone:** 781-235-3060

**E-mail:**

[ksharma@macbiocom.com](mailto:ksharma@macbiocom.com)

### Recent Headlines & Events

|   | <b>Date</b>                     | <b>Title</b>                       |
|---|---------------------------------|------------------------------------|
| 02/06/19 - 7:00 a.m.<br><a href="#">Exicure to Present at BIO CEO &amp; Investor Conference 2019</a>      | 02/21/19                        | <a href="#">RNA Therapeutics</a>   |
| 02/05/19 - 7:00 a.m.<br><a href="#">Exicure Announces US Clinical Sites for Phase 1b/2 Oncology Trial</a> | 03/01/19<br>through<br>03/05/19 | <a href="#">AAD Annual Meeting</a> |
| 02/04/19 - 7:00 a.m.<br><a href="#">Exicure to Present at the Immuno-Oncology 360° Conference</a>         | 03/25/19<br>through<br>03/27/19 | <a href="#">BIO-Europe</a>         |

### SEC Filings

| <b>Filing Date</b> | <b>Form</b>           |
|--------------------|-----------------------|
| 02/01/19           | <a href="#">8-K</a>   |
| 01/07/19           | <a href="#">8-K</a>   |
| 11/06/18           | <a href="#">424B3</a> |
| 11/06/18           | <a href="#">424B3</a> |

Data provided by Nasdaq. Minimum 15 minutes delayed.